Case Report

Improvement with Infliximab of a Disseminated Sarcoidosis in a Patient with Crohn's Disease

Nader Chebib,¹ Fabrice Piégay,^{1,2,3} Julie Traclet,¹
François Mion,^{1,2,3} and Jean-François Mornex^{1,2,3,4}

¹ Hospices Civils de Lyon, 69003 Lyon, France

² Université de Lyon, 69007 Lyon, France

³ Université Lyon1, 69007 Lyon, France

⁴ INRA, UMR754, 69007 Lyon, France

Correspondence should be addressed to Jean-François Mornex; mornex@univ-lyon1.fr

Received 24 November 2013; Accepted 31 December 2013; Published 6 February 2014

Academic Editors: E. Fernández Pérez, S. Ohshimo, T. Peros-Golubicic, and C. van Moorsel

Copyright © 2014 Nader Chebib et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sarcoidosis and Crohn's disease are systemic granulomatous disorders affecting the lung and the intestine, respectively, with variable involvement of other organs and are seldom associated. While anti-TNF α is a recognized treatment of Crohn's disease, its usage is discussed in sarcoidosis. A 42-year-old man presented with an 11-year-long history of Crohn's disease; upon discovery of an abnormal chest CT scan the diagnosis of multivisceral sarcoidosis was made and, later, a treatment with an anti-TNF α agent, infliximab, was started, because of worsening Crohn's disease recurrences. CT scan demonstrated net regression of pulmonary opacities and hepatosplenic lesions. Pathologies obtained from the intestinal tract and the bronchi of the patient were, respectively, characteristic of Crohn's disease and sarcoidosis leading to the diagnosis of both diseases. We report a rare case of steroid resistant Crohn's disease associated with multivisceral sarcoidosis, treated successfully by an anti-TNF α agent, infliximab.

1. Introduction

Both sarcoidosis and Crohn's disease are relapsing chronic inflammatory disorders characterized by the formation of granulomas; they share some organ locations, cytokine pathways, and genetic background. The association of both diseases has rarely been reported. If anti-TNF α is a recognized treatment of Crohn's disease, its role in sarcoidosis remains discussed. We report the association of both diseases in a single patient and the beneficial effect of anti-TNF α on both diseases.

2. Case Report

A 42-year-old man presented with a 3-month history of respiratory symptoms combining mild dyspnea, cough, asthenia, and weight loss. His past medical history included a 6-pack-year smoking habit and an 11-year-long history of Crohn's disease, treated with oral steroids (prednisolone 20 mg/day) ever since. Over time, repeated biopsies showing

ulceration and transmural inflammatory lesions of the ileum, the colon, and the rectum including submucosal aggregates of lymphocytes and plasmocytes and, once, rectal epithelioid granulomas were always consistent with the diagnosis. Physical exam showed no abnormalities. Peripheral blood lymphocyte count was decreased (890/ μ L including 374 CD4 lymphocytes/ μ L, i.e., 42%); serum angiotensin converting-enzyme level was elevated (118 U/L). CT scan was markedly abnormal (Figures 1(a), 1(b), and 1(c)) showing enlarged bilateral hilar and mediastinal lymph nodes, a left apical irregular nodule, bilateral perihilar infiltrates, upper lobe micronodules, proximal bronchial thickening, and hepatic and splenic nodules, along with retroperitoneal lymph nodes. All of these lesions were metabolically active on PET scan as well as osteolytic spinal, costal, clavicular, and humeral lesions (Figures 2(a), 2(b), and 2(c)). Bronchoscopy showed a bilateral diffuse inflammatory infiltration, and the bronchoalveolar lavage disclosed a predominant neutrophilic alveolitis (77% neutrophils, 8% lymphocytes, CD4/CD8 lymphocyte ratio = 1.9) in the absence of any viral, bacterial, or fungal

FIGURE 1: Chest ((a), (b), (d), and (e)) and abdominal ((c), (f)) CT scans showing resolution after treatment ((d), (e), and (f)) of diffuse lesions ((a), (b), and (c)).

microorganism. Cultures were negative for *Mycobacterium* sp. Bronchial biopsies noted the presence of noncaseating granulomas with epithelioid and multinucleated giant cells. The diagnosis of multivisceral sarcoidosis was made and inhaled steroids to ease the cough were the only treatment instated since the patient was already on oral steroids and the functional impact of the disease was mild; PFTs disclosed a mixed restrictive and obstructive pattern (Table 1). Four months later, a treatment with an anti-TNF α agent, infliximab, was started, because of worsening Crohn's disease recurrences; the dose regimen was 5 mg/Kg every 6 weeks. After 5 courses, oral steroids were successfully weaned, digestive symptoms were largely improved, the patient had gained weight and had no more cough, the dyspnea level diminished, and PFT abnormalities improved (Table 1). CT scan demonstrated net regression of pulmonary opacities and hepatosplenic lesions (Figures 1(d), 1(e), and 1(f)) with PET scan showing no more metabolic activity, except in the distal ileum area (SUV max 7.4) (Figures 2(d), 2(e), and 2(f)). Oral steroids were successfully weaned over a period of 6.5 months

since the start of infliximab, and the patient remains off steroids to this day. Blood CD4 lymphocyte count increased slightly to 411/ μ L (44%) and ACE level was not reassessed.

3. Discussion

Given the clinical presentation, the nosology of the digestive and the thoracic locations needs to be discussed. Gastrointestinal sarcoidosis, apart from being very rare, is mostly located in the stomach [1]. Lung involvement of inflammatory bowel diseases is mostly interstitial lung or bronchiolar disease and rarely granulomatous [2]. Lung nodules have been reported but are usually preceding Crohn's disease, mostly in children [3]. Finally, pathology obtained from the intestinal tract and the bronchi of the patient were, respectively, characteristic of Crohn's disease and sarcoidosis leading to the diagnosis of both diseases associated [4]. Of note, in a personal series, Reynolds reported 2 of 67 sarcoidosis patients with Crohn's disease [5]. Granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency

FIGURE 2: Chest ((a), (d)) and abdominal ((b), (c), (e), and (f)) PET scan showing hypermetabolism in pulmonary, hepatosplenic, spinal, and intestinal lesions before treatment ((a), (b), and (c)), markedly decreasing after treatment ((d), (e), and (f)) except for the distal ileum.

[6] could be discussed. This patient presented, in addition to Crohn's disease, with a severe multiorgan sarcoidosis [5]. BAL in our patient showed neutrophilia, which is an uncommon feature in sarcoidosis, notably in the absence of an infectious disease or active smoking but it can be observed in chronic forms of sarcoidosis and stage IV disease [7]. The residual hypermetabolism in the ileum on the PET scan is consistent with a persistent mucosal inflammation due to Crohn's disease. Recently, genomic studies revealed common genetic variants predisposing to either disease: on one hand, different SNPs in the NOD2/CARD15 genes with relevance to the pathogenesis [8, 9] and on the other hand, single SNPs increasing the risk of either disease but with no mechanistic relevance so far [10, 11]. Increased local secretion has long suggested that TNF α among other cytokines may play a role in both diseases [12, 13]. While anti-TNF α is a recognized treatment of Crohn's disease [14], it has been reported to be of clinical use in refractory or severe

TABLE 1: PFT results before and after treatment with infliximab.

	Before treatment	After treatment
FEV1/CV	63%	71%
FEV1	1.32 L (41%)	1.63 L (51%)
VC	2.08 L (52%)	2.31 L (59%)
RV	1.72 L (96%)	1.07 L (59%)
TLC	3.80 L (66%)	2.95 L (51%)
DLCO	35%	34%
KCO	79%	90%

sarcoidosis [15]. Sarcoidosis may occur during anti-TNF α treatment of Crohn's disease [16] and other inflammatory and rheumatic diseases [17, 18] and with other drugs interfering with the cell interaction processes [19]. In the present case, anti-TNF α was started after the diagnosis of sarcoidosis.

4. Conclusion

We report a rare case of steroid resistant Crohn's disease followed by multivisceral sarcoidosis, treated successfully by an anti-TNF α agent, infliximab. This is the first report to our knowledge of a simultaneous double response in both of these diseases to anti-TNF α therapy. Sarcoidosis and Crohn's disease are systemic granulomatous disorders affecting the lung and the intestine, respectively, with variable involvement of other organs. Differential is critical because, although they share many clinical, immunological, genetic and pathological aspects, treatment strategies are different including different clinical responses to anti-TNF α .

Conflict of Interests

The authors declare that there is no conflict of interests.

Authors' Contribution

All authors contributed to the conception of the study and the preparation and approval of the paper; in addition, Jean-François Mornex and François Mion directed the clinical care of the patient.

References

- [1] M. Esmadi, D. S. Ahmad, B. Odum et al., "Sarcoidosis: an extremely rare cause of granulomatous enterocolitis," *Journal of Gastrointestinal and Liver Diseases*, vol. 21, no. 4, pp. 423–425, 2012.
- [2] P. Camus and T. V. Colby, "The lung in inflammatory bowel disease," *European Respiratory Journal*, vol. 15, no. 1, pp. 5–10, 2000.
- [3] E. Pain-Prado, A. Rais, F. Madhi, C. Orzechowski, B. Dubern, and R. Epaud, "Pulmonary and hepatic nodular lesions precede the diagnosis of Crohn's disease in an 8-year-old girl: a case study and review of the literature," *Acta Paediatrica*, vol. 101, no. 2, pp. e86–e89, 2012.
- [4] L. Kallel, M. Fekih, I. Ben Ghorbel et al., "Un cas exceptionnel de sarcoidose systemique suivie par une maladie de Crohn: une association fortuite ou lien etiopathogenique?" *La Presse Médicale*, vol. 39, no. 1, pp. 148–150, 2010.
- [5] H. Y. Reynolds, "Sarcoidosis: impact of other illnesses on the presentation and management of multi-organ disease," *Lung*, vol. 180, no. 5, pp. 281–299, 2002.
- [6] J. H. Park and A. I. Levinson, "Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)," *Clinical Immunology*, vol. 134, no. 2, pp. 97–103, 2010.
- [7] M. Drent, K. Mansour, and C. Linssen, "Bronchoalveolar lavage in sarcoidosis," *Seminars in Respiratory and Critical Care Medicine*, vol. 28, no. 5, pp. 486–495, 2007.
- [8] C. H. van Moorsel and D. C. Christiani, "Genetic susceptibility to sarcoidosis, a chronic inflammatory disorder," *American Journal of Respiratory and Critical Care Medicine*, vol. 186, no. 9, pp. 816–818, 2012.
- [9] J. T. Tigno-Aranjuez and D. W. Abbott, "Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease," *Biochimica et Biophysica Acta*, vol. 1823, no. 11, pp. 2022–2028, 2012.
- [10] A. Franke, A. Fischer, M. Nothnagel et al., "Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2," *Gastroenterology*, vol. 135, no. 4, pp. 1207–1215, 2008.
- [11] A. Fischer, B. Schmid, D. Ellinghaus et al., "A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1," *American Journal of Respiratory and Critical Care Medicine*, vol. 186, no. 9, pp. 877–885, 2012.
- [12] J. F. Mornex, C. Leroux, T. Greenland, and D. Ecochard, "From granuloma to fibrosis in interstitial lung diseases: molecular and cellular interactions," *European Respiratory Journal*, vol. 7, no. 4, pp. 779–785, 1994.
- [13] C. Abraham and J. H. Cho, "Inflammatory bowel disease," *New England Journal of Medicine*, vol. 361, no. 21, pp. 2066–2078, 2009.
- [14] L. Peyrin-Biroulet, P. Deltenre, N. de Suray, J. Branche, W. J. Sandborn, and J. Colombel, "Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of Placebo-controlled trials," *Clinical Gastroenterology and Hepatology*, vol. 6, no. 6, pp. 644–653, 2008.
- [15] R. P. Baughman, E. E. Lower, and M. Drent, "Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them," *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, vol. 25, no. 2, pp. 76–89, 2008.
- [16] H. Takahashi, K. Kaneta, M. Honma et al., "Sarcoidosis during infliximab therapy for Crohn's disease," *Journal of Dermatology*, vol. 37, no. 5, pp. 471–474, 2010.
- [17] D. Tong, N. Manolios, G. Howe, and D. Spencer, "New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication," *Internal Medicine Journal*, vol. 42, no. 1, pp. 89–94, 2012.
- [18] L. Javot, S. Tala, J. Scala-Bertola et al., "Sarcoidosis and anti-TNF: a paradoxical class effect? Analysis of the French pharmacovigilance system database and literature review," *Thérapie*, vol. 66, no. 2, pp. 149–154, 2011.
- [19] C. A. Parisinos, C. W. Lees, W. A. H. Wallace, and J. Satsangi, "Sarcoidosis complicating treatment with natalizumab for Crohn's disease," *Thorax*, vol. 66, no. 12, pp. 1109–1110, 2011.